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dol. Inclusion criteria of treatment episodes were that the sub-
jects were aged 18 years or above, had had at least one admis-
sion due to schizophrenia during the two-year period prior to
the initiation of the treatment episodes, and with no diabetes
mellitus during a one-year period prior to the initiation of the
treatment episodes. Diabetes mellitus was identiﬁed by claims
with such diagnosis or with antidiabetic agents. A logistic regres-
sion model was applied to evaluate the likelihood of newly-onset
cases of diabetes of different antipsychotic treatment episodes.
Patient and clinical characteristics were included as covariates.
RESULTS: Compared with users of haloperidol, those receiving
clozapine, olanzapine, and risperidone had a higher probability
of developing diabetes mellitus. Those taking quetiapine, amisul-
pride, and ziprasidone, however, had no signiﬁcantly higher 
odds of developing diabetes mellitus. CONCLUSIONS: The pre-
liminary ﬁndings of this study support reports of atypical
antipsychotics-induced diabetes mellitus. Clozapine, olanzapine,
and risperidone, compared with haloperidol, are associated with
an increased risk of diabetes mellitus among schizophrenic
patients in Taiwan.
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OBJECTIVES: Describe the annual direct health care and indi-
rect work loss costs for employees treated with antidepressants
and compare them across patients with different treatment
response. METHODS: We examined 1999–2003 data from a
claims database of 1.2 million beneﬁciaries, from 7 large U.S.
employers. Analysis was restricted to employees aged 18–64,
with at least one diagnosis of major depressive disorder (ICD-9:
296.2x, 296.3x) and at least one prescription of selective 
serotonin or seratonin/norepinephrine reuptake inhibitor
(SSRI/SNRI). Patients were classiﬁed as combination antidepres-
sant therapy users, switchers, discontinuers, or monotherapy
maintainers. Annual direct health care costs, including drug and
medical costs (comprising inpatient, outpatient, and emergency
visits), and indirect work loss costs (comprising absenteeism and
disability) were calculated for the 12-month period following
therapy initiation. Results were compared descriptively across
treatment responses using t-tests and ANOVA analyses.
RESULTS: Of the 3971 patients, 18.4% were on combination
therapy, 19.7% switchers, 45.1% discontinuers, and 16.8%
monotherapy maintainers. Patients on combination therapy had
similar direct and indirect costs compared to switchers (all p >=
0.08). The average direct and indirect costs for patients on com-
bination therapy and switchers ($7986 and $2806 respectively)
were higher than those for discontinuers ($6013 and $1680
respectively, all p < 0.001) or maintainers ($5193 and $1467
respectively, all p < 0.001). Compared to patients on combina-
tion therapy and switchers, maintainers had similar drug costs
($1980 vs. $2068, p = 0.469). Compared to discontinuers, main-
tainers had higher drug costs ($1,980 vs. $1095, p < 0.001), but
lower medical ($3214 vs. $4918, p = 0.002) and disability costs
($360 vs. $664, p = 0.008). CONCLUSION: Patients on 
combination therapy or who switched monotherapy had higher
average direct health care costs and indirect work loss costs than
patients who discontinued or maintained therapy. Maintainers
had higher drug costs but lower medical and disability costs 
compared to discontinuers.
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OBJECTIVE: To estimate the incremental cost-effectiveness of
venlafaxine extended-release compared to Selective Serotonin
Reuptake Inhibitors (SSRIs) in the treatment of major depressive
disorder (MDD) in Canada. METHODS: A previously validated
decision-tree model for the treatment of MDD was adapted 
to the Canadian clinical practice setting. Probabilities used to
populate the decision-tree were derived from the literature and
where needed, from a Delphi panel consisting of two General
Practitioners and two Psychiatrists. The Ontario Ministry of
Health and Long-term Care perspective was used in this study.
The relevant direct medical costs (year 2005 Canadian dollar
values) were derived from the Ontario Health Insurance Policy
(OHIP) and the Ontario Case Costing Initiative (OCCI). The
drug acquisition cost for venlafaxine (brand) and SSRIs (generic)
was derived from the Ontario Drug Beneﬁt formulary (ODB).
The treatment goal in the model was achieving remission and the
primary outcome measure in the model was Symptom Free Days
(SFDs). The time horizon was six months; therefore the costs and
outcomes were not discounted. Various one-way sensitivity
analyses were performed. RESULTS: The average six-month
expected cost per patient for venlafaxine and SSRIs were
CDN$4156 and CDN$4224 respectively. The average six-month
expected SFDs were 53.4 and 46.7 days for venlafaxine and
SSRIs respectively. The cost-effectiveness as measured by cost per
SFDs was CDN$77.86 for venlafaxine and CDN$90.36 for
SSRIs. The incremental cost-effectiveness analysis showed a
treatment strategy using venlafaxine as ﬁrst line was dominant.
The sensitivity analysis demonstrated the results robustness to
variations in drug acquisition cost. CONCLUSION: Despite a
higher drug acquisition cost, venlafaxine extended-release may
be cost-effective and even cost saving compared to SSRIs when
used as ﬁrst line treatment of MDD in a Canadian clinical 
practice setting.
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OBJECTIVES: To estimate the cost-effectiveness of atypical
antipsychotics (AAPs) in the treatment of acute mania in patients
with bipolar I disorder from a managed care perspective.
METHODS: The model estimated the cost-effectiveness (CE)
ratios for each AAP when used as monotherapy for the acute (3-
week) treatment of patients with bipolar mania. CE ratios were
deﬁned as the total annual cost per responder, and responders
were deﬁned as patients with a 50% improvement on the 
YMRS scale at 3 weeks. Data sources included published litera-
ture, package inserts, and primary data analysis of a managed
care claims database. The median response rate for each AAP
was used in the base case scenario; 45.5%, 50.0%, 58.0%,
53.3%, and 56.7% for aripiprazole, ziprasidone, risperidone,
quetiapine, and olanzapine, respectively. Since there are no pub-
